Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Merck & Co (NY: MRK)
76.73 USD  +0.04 (+0.05%)
Official Closing Price  /  Updated: 7:57 PM EDT, Jul 10, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 4,925,000
Open 76.75
Bid (Size) 76.27 (1)
Ask (Size) 77.18 (5)
Prev. Close 76.69
Today's Range 76.40 - 77.35
52wk Range 65.25 - 92.64
Shares Outstanding 2,690,303,898
Dividend Yield 2.50%
Performance
YTD
-16.63%
-16.63%
1 Month
-0.80%
-0.80%
3 Month
-4.73%
-4.73%
6 Month
-14.28%
-14.28%
1 Year
-3.76%
-3.76%
Top News
More News
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews Read More
from Business Wire News Releases
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymph
FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Read More
from Business Wire News Releases
More News
Read More
Merck Announces Appointment of Organon & Co. General Counsel
from Business Wire News Releases
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
from Business Wire News Releases
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
from Business Wire News Releases
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
from Business Wire News Releases
Moderna and Other Coronavirus Vaccine Developers to Testify in Congress July 21
category MRK , PFE , Market News , and 3 more.
from Motley Fool
Regeneron Pharmaceuticals Stock Hits New High On Coronavirus Treatment Potential
from Investor's Business Daily
Dogs of the Dow: Why 2020 Is Sending This Popular Strategy to the Doghouse
category MRK , XOM , Market News , and 6 more.
from Motley Fool
CanSino's COVID-19 Vaccine Was Just Approved for Limited Use in China. Here's What Investors Should Know.
category MRK , JNJ , 6185 , and 2 more.
from Motley Fool
Market Briefing For Tuesday, July 7
category Technology , ETFs , Capital & Industrial Goods , and 4 more.
from Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.